NSE: PGHL | BSE: 500126

Strong Performer, Getting Expensive

Download real time

5907.00 32.50 (0.55%)

Near 52W High of ₹6175.50

5,533 NSE+BSE Volume

NSE 20 Jun, 2025 3:31 PM (IST)

9,805.3

Market Cap

Above industry Median

0.6

Beta 1Year

Very Low volatility

Procter & Gamble Health Ltd. share price target and research reports

Name: Latest research reports of Procter & Gamble Health Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Procter & Gamble Health Ltd.
Rating: 5
Author: ICICI Securities Limited

Latest analyst research reports with target prices and PDF download for PGHL, BSE:500126 Procter & Gamble Health Ltd.

Procter & Gamble Health Ltd.

19 Dec 2017

5907.00

0.55%

Merck Ltd

Buy: Procter & Gamble Health Ltd.

ICICI Securities Limited

Procter & Gamble Health Ltd. is trading above all available SMAs

Procter & Gamble Health Ltd.

16 Nov 2017

5907.00

0.55%

Merck

Hold: Procter & Gamble Health Ltd.

Centrum Broking

Pharma segment revenue grew 13%YoY: Merck's pharma segment's revenue grew 13%YoY to Rs2.45bn from Rs2.18bn due to re-stocking by trade post successful GST implementation. Merck is a pioneer in the vitamin segment, with three major brands Neurobion, Polybion and Evion. Evion does not fall under the National List of Essential Medicines (NLEM) and hence its price hasn't been capped. The company's chemical business (22% of revenues) grew by 12%YoY. We expect the high-margin pharma business to drive future growth. Margin grew by 140bps YoY: Merck's EBIDTA margin grew by 140bps YoY to...

Procter & Gamble Health Ltd. is trading above all available SMAs

Procter & Gamble Health Ltd.

15 Nov 2017

5907.00

0.55%

Result Review of Merck

Hold: Procter & Gamble Health Ltd.

IDBI Capital

EBITDA margin of 18.1% were higher than our estimates of 11.5%. Similarly, PAT of Rs317mn, +11.2% YoY, was higher than our estimates. We maintain our CY17E/18E estimates and TP (Rs1,179, 17x CY18E EPS+ CCE of Rs267/sh) and our rating of HOLD. Key Highlights and Investment Rationale India and other regions to fill the gap All players have seen the reversal patterns with the re-stocking happening in the channels which had got impacted during the last quarter due to the implementation...

Procter & Gamble Health Ltd. is trading above all available SMAs

Procter & Gamble Health Ltd.

08 Aug 2017

5907.00

0.55%

Result Review of Merck

Accumulate: Procter & Gamble Health Ltd.

IDBI Capital

Q2CY17 results were in-line with our estimates. Revenues were at Rs2.6bn lower by our estimates by 4.6% while Adj PAT was at Rs201mn, 3.2% above our estimate of Rs195mn. EBITDA margin of 10.7% were lower than our estimates of 11.1%, mainly on the back lower gross margins. During Q2CY17, profitability seems to be dented at the pharmaceuticals segment which accounted for 77% of its revenues, while the improvement in the chemicals segment helped to support the overall margins. We maintain our CY17E/18E estimates and TP (Rs1179, 17x CY18E EPS+ CCE of...

Procter & Gamble Health Ltd. is trading above all available SMAs

Procter & Gamble Health Ltd.

05 May 2017

5907.00

0.55%

Initiating Coverage on Merck Ltd

Accumulate: Procter & Gamble Health Ltd.

IDBI Capital

Merck KGaA, the parent company of Merck India (EMER), headquartered in Darmstadt, Germany is one of the oldest pharmaceuticals and chemicals company which was founded in 1668 and got listed in 1981. EMER has a market share of 0.6% in the IPM. We expect the EMER's pharmaceuticals portfolio to grow in-line with the industry growth on the back of its flagship brands (Evion, Livogen, Polybion, Nurobion, Nasivion and Seven Seas). Sustaining the Rank 1 position in the Vitamins/Minerals and Nutrients segment (50% of portfolio) is possible, however, negatively impacted by its large brands coming under the purview of the regulatory control and key concentration in few brands. Despite volume...

Procter & Gamble Health Ltd. is trading above all available SMAs

Procter & Gamble Health Ltd.

09 May 2015

5907.00

0.55%

Merck Ltd- 1Q CY15 Results: First Cut Lower Operating Expenses Drive Profits, In... (May 09, 2015)

Hold: Procter & Gamble Health Ltd.

Karvy

Merck Ltd reported Rs.1,988 Mn in Net Revenues, up by 2.6% YoY, but on a QoQ basis Net Revenues fell by 7.1%. EBITDA margin increased by 438 bps YoY to 6.5%. Lower expenses led to higher margins due to 1. Cost of Goods Sold (CoGS) as percentage of revenues decreased by 121 bps YoY (346 bps QoQ) and 2. Other Expenses as percentage of revenues decreased by 466 bps YoY (471 bps QoQ). EPS has increased from Rs.2.14 in Q1 CY14 to Rs.5.80 in Q1 CY15. During Q4 CY14 Merck reported EPS of Rs.0.65. Karvy initiated coverage report on Merck Ltd on May 04, 2015 with a Hold rating. We continue to maintain a Hold rating on Meck Ltd

Procter & Gamble Health Ltd. is trading above all available SMAs

Procter & Gamble Health Ltd.

04 May 2015

5907.00

0.55%

Merck Ltd: Added Injectables Capacity Alludes To Possible New Launches (May 04, 2015)

Hold: Procter & Gamble Health Ltd.

Karvy

Merck is currently increasing the capacity of its plant in Ponda, Goa. This could be a sign that Merck is planning for some new launches in injectables in the near future. Injectables are often high-margin products having the potential to boost profits.

Procter & Gamble Health Ltd. is trading above all available SMAs

Is Procter & Gamble Health Ltd. worth buying?

219 Votes:

Buy 72.6%

Sell 17.81%

Hold 9.59%